Erschienen in:
15.06.2019 | Research Article
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
verfasst von:
J. Gavilá, J. De La Haba, B. Bermejo, Á. Rodríguez-Lescure, A. Antón, E. Ciruelos, J. Brunet, E. Muñoz-Couselo, M. Santisteban, C. A. Rodríguez Sánchez, A. Santaballa, P. Sánchez Rovira, J. Á. García Sáenz, M. Ruiz-Borrego, A. L. Guerrero-Zotano, M. Huerta, A. Cotes-Sanchís, J. Lao Romera, E. Aguirre, J. Cortés, A. Llombart-Cussac
Erschienen in:
Clinical and Translational Oncology
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L.
Materials and methods
We conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L–T. Concomitant endocrine therapy, as well as brain metastasis and/or prior exposure to L, were allowed.
Results
One hundred and fifteen patients from 14 institutions were included. The median age was 59.8 years. The median number of prior T regimens in the advanced setting was 3 and 73 patients had received a prior L regimen. The clinical benefit rate (CBR) was 34.8% (95% CI 26.1–43.5). Among other efficacy endpoints, the overall response rate was 21.7%, and median progression-free survival (PFS) and overall survival were 3.9 and 21.6 months, respectively. Heavily pretreated and ≥ 3 metastatic organ patients showed lower CBR and PFS than patients with a low number of previous regimens and < 3 metastatic organs. Moreover, CBR did not significantly change in L-pretreated compared with L-naïve patients (31.5% versus 40.5% for L-pretreated versus L-naïve). Grade 3/4 adverse events were reported in 19 patients (16.5%).
Conclusion
The combination of L–T is an effective and well-tolerated regimen in heavily pretreated patients and remains active among patients progressing on prior L-based therapy. Our study suggests that the L–T regimen is a safe and active chemotherapy-free option for MBC patients previously treated with T and/or L.